Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3824297 | 0.98 | PDPK1 (0.45) | PDPK1CYP3A4CYP2D6MAP3K11CYP2C9 | |
| Hydrochloric Acid SCHEMBL2369316 | 0.98 | PDPK1 (0.45) | PDPK1CYP3A4CYP2D6MAP3K11CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL30678615 | 0.84 | HDAC6 (0.46) | PDPK1CYP3A4CYP2D6MAP3K11CYP2C9 | |
| SCHEMBL12276737 | 0.83 | PDPK1 (0.47) | PDPK1CYP3A4CYP2D6MAP3K11CYP2C9 | |
| SCHEMBL8296659 | 0.75 | CYP2A6 (0.47) | HDAC6MAPTGPR84AHRNR4A2 | |
| SCHEMBL30354467 | 0.75 | USP2 (0.50) | HDAC6MAPTGPR84AHRNR4A2 | |
| SCHEMBL587359 | 0.75 | AHR (0.50) | HDAC6MAPTGPR84AHRNR4A2 | |
| SCHEMBL21090062 | 0.75 | HDAC6 (0.43) | HDAC6MAPTGPR84AHRNR4A2 | |
| SCHEMBL29975686 | 0.75 | AHR (0.50) | HDAC6MAPTGPR84AHRNR4A2 | |
| SCHEMBL14041127 | 0.75 | GPR84 (0.52) | HDAC6MAPTGPR84AHRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-4635953-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Iregene Therapeutics Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4635954-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | Iregene Therapeutics Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024124464-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124463-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124463-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124464-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3221317-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| US-9738640-B2 | Substituted benzamide derivatives as in vitro MAO-B inhibitors | “NTZ LAB” LTD. (BG) | 2017-08-22 | — | — | US | disclosed |
| EP-2991986-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS MAO-B INHIBITORS | NTZ LAB LTD (BG) | 2017-03-08 | — | — | EP | disclosed |
| WO-2016155884-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
| US-20160152611-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2016-06-02 | — | — | US | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| EP-2991986-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ Lab" Ltd. (BG) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015013777-A9 | SUBSTITUTED BENZAMIDE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2015-11-19 | — | — | WO | disclosed |
| US-5807857-A | Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152611-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | MAOB, MAOA, AOC3 | PDPK1 3295/4885CYP3A4 190/4885CYP2D6 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.